You are here

Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Innsbruck, , A6020 Austria
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies, Complex Partial Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must have met the inclusion criteria for Study 1008-157, have received
double-blind study medication, and wish to receive open-label pregabalin

- Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial
seizures during the 6 weeks prior to screening

- Be currently taking 1 to 3 AEDs.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Have a treatable cause of seizures

- Experienced a serious adverse event during Study 1008-157 which was determined to be
possibly related to study medication

NCT00143143
Pfizer
Completed
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Partial Epilepsies
NCT00351611
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now